Navigation Links
Research Report on BioClinica, Inc. as Speculative Buy
Date:11/29/2009

ATLANTA, Nov. 29 /PRNewswire/ -- The following is an investment opinion release issued by Intellivest Securities Research, Inc.

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries. A primary service is helping their clients manage, process and submit medical imaging portions of their submissions relating to their clinical trials to regulators, primarily the U.S. Food and Drug Administration and comparable European agencies, to evaluate product efficacy and safety. BioClinica has provided services to more than 130 firms in connection with over 2,000 clinical partners since its founding in 1990.

The Research Report rates BioClinica, Inc. as a Speculative Buy because the FDA and other regulators are encouraging more clinical trial data to be submitted in an electronic format. As an early mover in this area, BioClinica is well positioned to exploit this trend. BIOC has a strong balance sheet and an attractive valuation. It has no debt, adequate cash, growing positive cash flow and enjoys significant operating leverage. BioClinica's shares are currently trading around two times book value and one times revenue. It has an experienced, highly competent management team, who, along with Board members, own about 9% of outstanding shares. BIOC has worked with the world's leading bio-pharmaceutical companies including three that are Dow Jones Industrial Average components: Johnson & Johnson, Merck, and Pfizer.

BioClinica has recently completed the integration of its two most recent acquisitions both of which should be accretive in 2010. BIOC reported positive results for the third quarter ending 9/30.

The Report states that BioClinica faces a number of risks including the uncertainty facing the entire pharmaceutical industry as a result of proposed health reform legislation.

About the Report

Intellivest Securities Research, Inc.'s research is distributed by Intellivest Securities, Inc., (FINRA, SIPC, RIA, SIFMA), whose Office of Supervisory Jurisdiction is located at 1540 Chase Court, Riverdale, GA. 30296-2610. Please read the Research Report for certain disclaimers and disclosures. Daniel H. Kolber is the author of the Report and www.DowJonesMonitor.com, a daily blog that aggregates articles about the Dow Jones 30 components (not affiliated with Dow Jones). He holds these licenses: Series 24, 27, 87, 53, 4, 79, 65; is a member of the Georgia, New York, Florida and Virginia Bars, and has the B.A. from Boston University, the J.D. from University of Virginia School of Law and the Ll.M. from New York University School of Law.

Intellivest Securities Research, Inc.'s (CRD #147288) research is distributed as third party research by its affiliate, Intellivest Securities, Inc. (CRD #145022) which is a member of the Financial Industry Regulatory Authority,.

www.intellivestsecurities.com

SOURCE Intellivest Securities Research, Inc.


'/>"/>
SOURCE Intellivest Securities Research, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Research sheds light on workings of anti-cancer drug
2. Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
3. MISSION Skincare(R) Supports GNCs Efforts To Raise Money for St. Jude Childrens Research Hospital(R)
4. Researchers identify proteins in lung cancer cells that may provide potential drug targets
5. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
6. Research Yields Clues to Severe Form of Sinusitis
7. AIDS research reveals a lack of family-planning programs in Uganda
8. Ann Taylor Stores Corp. Returns To St. Jude Childrens Research Hospitals Thanks and Giving Campaign(R) For The Third Year
9. New research shows versatility of amniotic fluid stem cells
10. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
11. Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
(Date:2/6/2016)... FL (PRWEB) , ... February 06, 2016 , ... ... pleased to announce the launch of a new DRTV campaign with Belly Bands. , ... having tried everything from sprays to puppy pads and find nothing works, get ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... Rosa, CA (PRWEB) , ... February 05, 2016 ... ... pleased to announce the addition of micro-needling services in their Napa Valley office. ... The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
Breaking Medicine Technology: